EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis

被引:125
|
作者
Crea, Francesco [1 ]
Fornaro, Lorenzo [2 ,3 ]
Bocci, Guido [1 ,4 ]
Sun, Lei [5 ]
Farrar, William L. [5 ]
Falcone, Alfredo [2 ]
Danesi, Romano [1 ]
机构
[1] Univ Pisa, Div Pharmacol, Dept Internal Med, I-56126 Pisa, Italy
[2] Univ Pisa, Div Med Oncol Transplants & New Technol Med, Dept Oncol, I-56126 Pisa, Italy
[3] Scuola Super Studi Univ & Perfezionamento St Anna, Inst Life Sci, I-56127 Pisa, Italy
[4] Ist Toscano Tumori, I-50139 Florence, Italy
[5] Frederick Natl Lab Canc Res, Canc Stem Cell Sect, Lab Canc Prevent, Frederick, MD USA
关键词
EZH2; Metastasis; Angiogenesis; DZNeP; Polycomb; HISTONE METHYLTRANSFERASE EZH2; GENE-EXPRESSION; NEOADJUVANT CHEMOTHERAPY; MESENCHYMAL TRANSITION; ANTITUMOR-ACTIVITY; STEM-CELLS; CANCER; POLYCOMB; BEVACIZUMAB; METASTASIS;
D O I
10.1007/s10555-012-9387-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumor angiogenesis and metastatic spreading are two highly interconnected phenomena, which contribute to cancer-associated deaths. Thus, the identification of novel strategies to target angiogenesis and metastatic spreading is crucial. Polycomb genes are a set of epigenetic effectors, structured in multimeric repressive complexes. EZH2 is the catalytic subunit of Polycomb repressive complex 2 (PRC2), which methylates histone H3 lysine 27, thereby silencing several tumor-suppressor genes. EZH2 is essential for cancer stem cell self-renewal. Interestingly, cancer stem cells are thought to be the seeds of metastatic spreading and are able to differentiate into tumor-associated endothelial cells. Pre-clinical studies showed that EZH2 is able to silence several anti-metastatic genes ( e.g., E-cadherin and tissue inhibitors of metalloproteinases), thereby favoring cell invasion and anchorage-independent growth. In addition, EZH2 seems to play a crucial role in the regulation of tumor angiogenesis. High EZH2 expression predicts poor prognosis, high grade, and high stage in several cancer types. Recently, a small molecule inhibitor of PRC2 (DZNeP) demonstrated promising anti-tumor activity, both in vitro and in vivo. Interestingly, DZNeP was able to inhibit cancer cell invasion and tumor angiogenesis in prostate and brain cancers, respectively. At tumor-inhibiting doses, DZNeP is not harmful for non-transformed cells. In the present manuscript, we review current evidence supporting a role of EZH2 in metastatic spreading and tumor angiogenesis. Using Oncomine datasets, we show that DZNeP targets are specifically silenced in some metastatic cancers, and some of them may inhibit angiogenesis. Based on this evidence, we propose the development of EZH2 inhibitors as anti-angiogenic and anti-metastatic therapy.
引用
收藏
页码:753 / 761
页数:9
相关论文
共 50 条
  • [1] EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis
    Francesco Crea
    Lorenzo Fornaro
    Guido Bocci
    Lei Sun
    William L. Farrar
    Alfredo Falcone
    Romano Danesi
    Cancer and Metastasis Reviews, 2012, 31 : 753 - 761
  • [2] Regulation of Tumor Angiogenesis by EZH2
    Lu, Chunhua
    Han, Hee Dong
    Mangala, Lingegowda S.
    Ali-Fehmi, Rouba
    Newton, Christopher S.
    Ozbun, Laurent
    Armaiz-Pena, Guillermo N.
    Hu, Wei
    Stone, Rebecca L.
    Munkarah, Adnan
    Ravoori, Murali K.
    Shahzad, Mian M. K.
    Lee, Jeong-Won
    Mora, Edna
    Langley, Robert R.
    Carroll, Amy R.
    Matsuo, Koji
    Spannuth, Whitney A.
    Schmandt, Rosemarie
    Jennings, Nicholas B.
    Goodman, Blake W.
    Jaffe, Robert B.
    Nick, Alpa M.
    Kim, Hye Sun
    Guven, Eylem Ozturk
    Chen, Ya-Huey
    Li, Long-Yuan
    Hsu, Ming-Chuan
    Coleman, Robert L.
    Calin, George A.
    Denkbas, Emir B.
    Lim, Jae Yun
    Lee, Ju-Seog
    Kundra, Vikas
    Birrer, Michael J.
    Hung, Mien-Chie
    Lopez-Berestein, Gabriel
    Sood, Anil K.
    CANCER CELL, 2010, 18 (02) : 185 - 197
  • [3] Targeting epigenetics in sarcomas through EZH2 inhibition
    Italiano, Antoine
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
  • [4] Targeting epigenetics in sarcomas through EZH2 inhibition
    Antoine Italiano
    Journal of Hematology & Oncology, 13
  • [5] Inhibition of EZH2 Stops Fibrosis and Improves Angiogenesis in Scleroderma
    Tsou, Pei-Suen
    Campbell, Phillip L.
    Amin, M. Asif
    Coit, Patrick
    Fox, David
    Khanna, Dinesh
    Sawalha, Amr H.
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [6] Targeting EZH2 in cancer
    Kimberly H Kim
    Charles W M Roberts
    Nature Medicine, 2016, 22 : 128 - 134
  • [7] Targeting EZH2 with tazemetostat
    Makita, Shinichi
    Tobinai, Kensei
    LANCET ONCOLOGY, 2018, 19 (05): : 586 - 587
  • [8] Inhibition of EZH2 prevents fibrosis and restores normal angiogenesis in scleroderma
    Tsou, Pei-Suen
    Campbell, Phillip
    Amin, M. Asif
    Coit, Patrick
    Miller, Shaylynn
    Fox, David A.
    Khanna, Dinesh
    Sawalha, Amr H.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (09) : 3695 - 3702
  • [9] Targeting EZH2 in cancer
    Kim, Kimberly H.
    Roberts, Charles W. M.
    NATURE MEDICINE, 2016, 22 (02) : 128 - 134
  • [10] Targeting EZH2 functions
    Kleer, C. G.
    CANCER RESEARCH, 2022, 82 (04)